ijms-logo

Journal Browser

Journal Browser

Endometrial Cancer: From Basic Science to Novel Therapeutics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 2105

Special Issue Editor


E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 18450, Korea
Interests: cervical cancer; HPV infection; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advancements in endometrial cancer research have significantly improved the diagnosis, treatment, and understanding of the disease's molecular characteristics. Molecular and genomic profiling now allows for enhanced cancer classification, facilitating personalized treatment approaches targeting specific genetic mutations and molecular subtypes. Immunotherapy has emerged as a promising option for advanced or recurrent cases, with drugs like pembrolizumab and dostarlimab showing efficacy in mismatch repair-deficient tumors. Despite progress, challenges remain in areas such as molecular analysis, personalized treatments, and prognosis. This Special Issue focuses on advancing endometrial cancer research by presenting original studies and reviews that highlight novel discoveries, technical innovations, and translational applications, fostering open access to knowledge and driving advancements in diagnostics and therapeutics.

Topics of this Special Issue include, but are not limited to, the following: endometrial cancer; molecular tumor pathology; tumor microenvironment; cancer epidemiology and prevention; biomarkers: screening, diagnosis, treatment response, prognosis; cancer therapy: target discovery, drug design, resistance, targeted therapy, and personalized medicine; genomic and proteomic databases and applications.

Dr. Hye-Yon Cho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • molecular tumor pathology
  • tumor microenvironment
  • cancer epidemiology and prevention
  • biomarkers
  • cancer therapy
  • genomic and proteomic databases and applications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 3664 KB  
Article
Feasibility of Manufacturing and Antitumor Activity of TIL for Advanced Endometrial Cancers
by Yongliang Zhang, Kathleen N. Moore, Amir A. Jazaeri, Judy Fang, Ilabahen Patel, Andrew Yuhas, Patrick Innamarato, Nathan Gilbert, Joseph W. Dean, Behzad Damirchi, Joe Yglesias, Rongsu Qi, Michelle R. Simpson-Abelson, Erwin Cammaart, Sean R. R. Hall and Hequn Yin
Int. J. Mol. Sci. 2025, 26(15), 7151; https://doi.org/10.3390/ijms26157151 - 24 Jul 2025
Viewed by 1760
Abstract
Lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy approved for advanced melanoma, demonstrates promise for treating other solid tumors, including endometrial cancer (EC). The current study evaluates the feasibility of manufacturing TILs from EC tumors using Iovance’s proprietary 22-day Gen2 manufacturing process. Key parameters, [...] Read more.
Lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy approved for advanced melanoma, demonstrates promise for treating other solid tumors, including endometrial cancer (EC). The current study evaluates the feasibility of manufacturing TILs from EC tumors using Iovance’s proprietary 22-day Gen2 manufacturing process. Key parameters, including TIL yield, viability, immune phenotype, T-cell receptor clonality, and cytotoxic activity, were assessed. Of the 11 EC tumor samples processed at research scale, 10 (91%) successfully generated >1 × 109 viable TIL cells, with a median yield of 1.1 × 1010 cells and a median viability of 82.8%. Of the four EC tumor samples processed at full scale, all achieved the pre-specified TVC and viability targets. Putative tumor-reactive T-cell clones were maintained throughout the manufacturing process. Functional reactivity was evidenced by the upregulation of 4-1BB in CD8+ T cells, OX40 in CD4+ T cells, and increased production of IFN-γ and TNF-α upon autologous tumor stimulation. Furthermore, antitumor activity was confirmed using an in vitro autologous tumor organoid killing assay. These findings demonstrate the feasibility of ex vivo TIL expansion from EC tumors. This study provides a rationale for the initiation of the phase II clinical trial IOV-END-201 (NCT06481592) to evaluate lifileucel in patients with advanced EC. Full article
(This article belongs to the Special Issue Endometrial Cancer: From Basic Science to Novel Therapeutics)
Show Figures

Figure 1

Back to TopTop